Biopharmaceutical company NanoBio Corporation announced on Monday a change in corporate name to BlueWillow Biologics to reflect its evolution to a vaccines-focused company as well as its commitment to advancing its novel intranasal technology to develop new vaccines for several diseases.
Additionally, the company has completed a USD10m Series A financing led by North Coast Technology Investors, Line Moon Ventures and the University of Michigan through its MINTS initiative.
Headquartered in Ann Arbor, Michigan, BlueWillow Biologics® is a privately-held biopharmaceutical company, focused on developing and commercializing intranasal vaccines using its patented NanoVax technology platform. The technology employs a novel oil-in-water nanoemulsion adjuvant that is effective when administered via intranasal or intramuscular vaccination, and can elicit both mucosal and systemic immunity when applied intranasally.
Currently, BlueWillow is developing intranasal vaccines for several respiratory and sexually transmitted infections, including RSV, pertussis, influenza, anthrax, prophylactic and therapeutic HSV-2 and chlamydia.
Concurrently, BlueWillow will continue to develop skin and wound treatments through partnerships and external collaborations under the prior NanoBio trademark.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine